Soliton Inc

Soliton — Investor Presentation (June 2019)

36 slides from Soliton's investor presentation, Jun 4, 2019

  1. Slide 1: Soliton: Rapid Acoustic Pulse Technology

    soliton Rapid Acoustic Pulse Technology (Nasdaq: SOLY)

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer “The words “beleve,” “may.” “Wil “estat,” “continue, anticipate," intend," “expect.” oer, factors, inducing 1A. isk Factors" Moreover, toime the extent to we may make. In ght ofthese risk ‘More detaled

  3. Slide 3: Overview summary

    Overview summary ic and proprietary Rapid ‘Acoustic Pulse (RAP) technology Induces rget nd vacuoles No cavitation, heat or collateral tissue damage or pain Platform technology ‘Tattoo removal in as little as 1/3 the number office visits Cellulite reduction (Proof of Concept clinical results) Keloids

  4. Slide 4: Brief History

    Brief History Started 2012 with technology from MD Anderson MDAnderson Cancer Center Ganeer Center Founding inventor, from MIT, originated technology Mit that became Dexcom ($11 billion valuation as of 12/31/18) = $27 million investment from single Venture Capital pexcom Fund (also participated in o

  5. Slide 5: Management and Directors

    Management and Directors All life science veterans Multiple device clearances Multiple national and international aesthetic device launches

  6. Slide 6: Science Advisory Board

    Science Advisory Board High profile Key Opinion Leaders Strong podium presence Respected, published researchers Also members of Allergan’s CoolSculpting Medical Advisory Board Michael S. Kaminer, M.D. (Chairy" Elizabeth Tanzi, M.D.

  7. Slide 7: 1.0MPa

    1.0MPa

  8. Slide 8: RAP Device

    RAP Device 4 —

  9. Slide 9: Electrode Cartridge

    Electrode Cartridge Electro-hydraulics (arc plasma in saline) utilizes 3000 volts at 3000 amps; creates shockwaves from 2 to 6 MPa @ 100 Hz Electronic wave shaping enables very high repetition rate; reduces unwanted frequencies that cause heat and pain Custom designed reflector eliminates cavitation

  10. Slide 10: Platform Technology

    Platform Technology Medium settings = vacuole/cell disruption Rapid Acoustic Pulse (RAP) llulite Reduction High settings = ECM disruption (Acoustic Subcision) Keloid/Fibrotic Treatment

  11. Slide 11: Tattoo Removal: First Indication

    Tattoo Removal: First Indication soliton

  12. Slide 12: Million Americans want some form of tattoo removal

    44 million Americans want some form of tattoo removal 6 considering Total US — ‘Adult Population pets 44 million aan US prospects So, why isn’t this already a billion dollar business? soliton

  13. Slide 13: Current standard of care (laser removal) presents huge barriers

    Current standard of Cal (laser removal) pres: huge barriers A complete removal for this patient — could mean repeating this visit 10 more times over the next 1 to 2 (December 2012 Archives of Dermatology) Reducing this timeline will truly cha the industry approach soliton

  14. Slide 14: What limits a laser's effectiveness?

    What limits a laser’s effectiveness? removal may take _ 100. ‘one year or more to 2 achieve success ge i é g 60. 8 3 E 20. é 70 % No, of Treatment Sessions

  15. Slide 15: Two Major Causes of Laser Shielding

    Two Major Causes of Laser Shielding __ Laser Energy Epidermis -2 Dermis + Affected Particles Pigment Particles Joles (temporary bubbles) eflect up to 8 Topmost pigment particles Dermal vai shield those beneath of laser energy

  16. Slide 16: How Soliton RAP enables multiple laser passes

    Here’s how we believe Soliton RAP enables multiple laser passes soliton

  17. Slide 17: RAP Device Enables Multiple Laser Treatments In One Visit

    RAP Device Enables Multiple Laser Treatments In One Visit FDA clearance clinical trials: Demonstrated that Soliton’s RAP device enables multiple laser passes in a single Office visit Achieved tattoo fading results with our RAP device in 2-3 visits that may normally require 10 or more office visits w

  18. Slide 18: Statistically Significant Clinical Results

    Statistically Significant Clinical Results After approximately 3 office visits, the Soliton RAP delivered 75% or greater fading in 100% of patients* Soliton outperformed “laser- only” 100%* of the time Fading After 3 Treatments j 7 505% i i 7 250% dam 167% i Soliton oo : : Laser-Only nd graded acing

  19. Slide 19: Complete removal of treated ink after treatments

    Complete removal of treated ink after 3 treatments After 3 Treatments soliton .

  20. Slide 20: Complete removal of treated ink after treatments

    Complete removal of treated ink after 3 treatments Before After 3 Treatments soliton

  21. Slide 21: Soliton RAP changes the removal timeline

    Compared with historical controls, Soliton RAP changes the removal timeline R go é $ oo. 3 5 — Soiton (fading 290%) z 20. — Solton (tang 275%) é — Arch Derm Study, Laser-Only oe 5 70 % 20 'No. of Treatment Sessions

  22. Slide 22: Cellulite Treatment: Second Indication

    Cellulite Treatment: Second Indication soliton

  23. Slide 23: Cellulite

    Cellulite Cellulite is formed in the subdermal fat layer In this region, fat cells are arranged in chambers surrounded by bands of fibrous septa In certain types of cellulite, the septa can contract and become sclerotic holding portions of the skin with a non-flexible length of septa This results in

  24. Slide 24: Current Standard of Care

    Current Standard of Care Celifina is a surgical procedure used for treating depressed cutaneous scars, wrinkles, and cellulite dimples and ridges The principle of this procedure is to cut the fibrotic strands, which tether the scar to the underlying muscle The defect or depression is lifted by the r

  25. Slide 25: Acoustic subcision device: mechanism of action

    Acoustic subcision device: mechanism of action Our device emits rapid acoustic shock wave pulses that are transmitted through the skin to break the fibrotic septa ee Defects or depressions are lifted by the releasing action of the procedure Direct mechanism is shearing and tearing induced by shock w

  26. Slide 26: Acoustic subcision > fibrous septa disruption

    Acoustic subcision > fibrous septa disruption (Pig model. High intensity 2 minutes — 2x magnification) Control: Un-damaged fibrous septa Test: Fibrous septa disruption

  27. Slide 27: Acoustic subcision > Fibrous septa disruption

    Acoustic subcision > Fibrous septa disruption (Pig model. High intensity 2 minutes -- 20x magnification) Test: Fibrous septa disruption Control: Un-damaged fibrous septa (post-treatment)

  28. Slide 28: Proof of Concept Cellulite Trial

    roof of Concept Cellulite Tia ‘Single-Tx 12-Week Cellulite Severity Scores 1.24 point decrease in the ‘Average Score of $ Blinded Reviewers average CSS ‘st P<0.001 29% reduction in score oe of the ~120 total 4.00 “0 tions, participants reported 35 opain (score ot'0) 30 283 4 M 100% correct selection

  29. Slide 29: Clinically significant cellulite reduction with RAP

    Clinically significant cellulite reduction with RAP Before le Treatment Before and 12-weeks after a single 20 minute RAP treatment

  30. Slide 30: Cellulite solution that lasts

    soliton Celebrate a cellulite solution that lasts! BEFORE AFTER 3 YEARS Cellfina Comparative Photos

  31. Slide 31: RAP results continue to improve months post-treatment

    RAP results continue to improve 6 months post-treatment Before After 12 Weeks 26 Weeks After Single Treatment No pain, bruising or post-treatment discomfort or downtime

  32. Slide 32: Revenue Potential

    Revenue Potential Tattoo opportunity: Global market projected to be over $4B by 2023* Cellulite opportunity: Global market projected to be over $1.4B by 2026

  33. Slide 33: Device and revenue strategy

    Device and revenue strategy I “razor and blade” recurring revenue model Replaceable consumable cartridge good for one patient visit Sell or lease Hand piece contains consoles replaceable cartridge

  34. Slide 34: Key Milestones

    Key Milestones llestone Expected Timir FDA Approval for Tattoo indication May 2019 Complete Cellulite POC study- 26 week time point | May 2019 Complete | Cellulite POC 26 week data release in Las Vegas Aesthetics Show July 2019 Pivotal tial for Cellulite to be initiated | ia 2019 | POC study for Kel

  35. Slide 35: Capitalization Table

    Capitalization Table (as of ay 31, 2019) Average Exerci Conversion Price Shares Common Stock 14,965,182 | Warrants | 70.857 $1 75 Options 2,671,750 $1.82, Convertible Debt | 273,004 $0.1 75 TOTAL FDSO | 18,880,323

  36. Slide 36: Thank you

    soliton Rapid Acoustic Pulse Technology (Nasdaq: SOLY) Thank you

Soliton — Investor Presentation (June 2019) on 6ix